Skip to main content
Journal cover image

Overview of bladder cancer trials in the Cancer and Leukemia Group B.

Publication ,  Journal Article
Small, EJ; Halabi, S; Dalbagni, G; Pruthi, R; Phillips, G; Edelman, M; Bajorin, D; Cancer and Leukemia Group B,
Published in: Cancer
April 15, 2003

The Cancer and Leukemia Group B (CALGB) Genitourinary Committee has developed a broad range of clinical trials across most stages of bladder cancer. Recurrence rates of superficial bladder cancer after transurethral resection range from 50-70%. Although adjuvant bacillus Calmette-Guerin reduces the risk of disease recurrence or progression, only 30% of patients have long-term disease-free survival. Because the development of novel secondline agents is needed, the CALGB is evaluating the utility of intravesicle gemcitabine as well as an oral proapoptotic agent (CP-461). In patients with locally advanced disease with an increased risk of disease recurrence after cystectomy, a randomized trial of conventional chemotherapy versus sequential dose-dense therapy is under development. The gemcitabine/cisplatin combination has become a commonly used regimen for the treatment of advanced transitional cell carcinoma (TCC). The CALGB is undertaking a Phase II study that incorporates a fixed dose rate gemcitabine infusion in this regimen, together with a selective epidermal growth factor receptor tyrosine kinase inhibitor, Iressa (Astra Zeneca, Wilmington, DE). In patients with renal insufficiency, a regimen of carboplatin, gemcitabine, and Iressa is planned. Novel agents, including arsenic trioxide and trastuzumab (Herceptin; Genentech, Inc., South San Francisco, CA), are being evaluated as secondline therapy in patients with advanced TCC who have disease progression after frontline therapy.

Duke Scholars

Published In

Cancer

DOI

ISSN

0008-543X

Publication Date

April 15, 2003

Volume

97

Issue

8 Suppl

Start / End Page

2090 / 2098

Location

United States

Related Subject Headings

  • Urinary Bladder Neoplasms
  • Oncology & Carcinogenesis
  • Humans
  • Clinical Trials as Topic
  • Carcinoma, Transitional Cell
  • Antineoplastic Combined Chemotherapy Protocols
  • 4206 Public health
  • 3211 Oncology and carcinogenesis
  • 1117 Public Health and Health Services
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Small, E. J., Halabi, S., Dalbagni, G., Pruthi, R., Phillips, G., Edelman, M., … Cancer and Leukemia Group B, . (2003). Overview of bladder cancer trials in the Cancer and Leukemia Group B. Cancer, 97(8 Suppl), 2090–2098. https://doi.org/10.1002/cncr.11299
Small, Eric J., Susan Halabi, Guido Dalbagni, Raj Pruthi, George Phillips, Martin Edelman, Dean Bajorin, and Dean Cancer and Leukemia Group B. “Overview of bladder cancer trials in the Cancer and Leukemia Group B.Cancer 97, no. 8 Suppl (April 15, 2003): 2090–98. https://doi.org/10.1002/cncr.11299.
Small EJ, Halabi S, Dalbagni G, Pruthi R, Phillips G, Edelman M, et al. Overview of bladder cancer trials in the Cancer and Leukemia Group B. Cancer. 2003 Apr 15;97(8 Suppl):2090–8.
Small, Eric J., et al. “Overview of bladder cancer trials in the Cancer and Leukemia Group B.Cancer, vol. 97, no. 8 Suppl, Apr. 2003, pp. 2090–98. Pubmed, doi:10.1002/cncr.11299.
Small EJ, Halabi S, Dalbagni G, Pruthi R, Phillips G, Edelman M, Bajorin D, Cancer and Leukemia Group B. Overview of bladder cancer trials in the Cancer and Leukemia Group B. Cancer. 2003 Apr 15;97(8 Suppl):2090–2098.
Journal cover image

Published In

Cancer

DOI

ISSN

0008-543X

Publication Date

April 15, 2003

Volume

97

Issue

8 Suppl

Start / End Page

2090 / 2098

Location

United States

Related Subject Headings

  • Urinary Bladder Neoplasms
  • Oncology & Carcinogenesis
  • Humans
  • Clinical Trials as Topic
  • Carcinoma, Transitional Cell
  • Antineoplastic Combined Chemotherapy Protocols
  • 4206 Public health
  • 3211 Oncology and carcinogenesis
  • 1117 Public Health and Health Services
  • 1112 Oncology and Carcinogenesis